Literature DB >> 23064489

Preoperative echocardiographic-defined moderate-severe pulmonary hypertension predicts prolonged duration of mechanical ventilation following lung transplantation for patients with COPD.

Jeremy P Wrobel1, Bruce R Thompson, Gregory I Snell, Trevor J Williams.   

Abstract

PURPOSE: Recent studies have suggested that pretransplant secondary pulmonary hypertension (PHT) may be associated with worse outcomes following lung transplantation. We sought to determine whether COPD patients with secondary PHT have inferior intensive care outcomes following lung transplantation.
METHODS: This is a single-center, retrospective analysis of all lung transplant recipients between 2000 and 2009 for a primary diagnosis of COPD. Patients were stratified a priori into three pulmonary arterial pressure groups based on right ventricular systolic pressure (RVSP): no PHT (RVSP < 35 mmHg), mild PHT (35 ≤ RVSP < 45 mmHg), and moderate-severe PHT (RVSP ≥ 45 mmHg). Outcome measures were duration of mechanical ventilation, intensive care unit (ICU) length of stay, and PaO(2)/fraction inspired oxygen (PaO(2)/F(I)O(2)) ratio at 24 h posttransplantation.
RESULTS: A total of 46 COPD lung transplant recipients with documented pretransplant RVSP were included in the analysis, including 18 with no PHT, 20 with mild PHT, and eight with moderate-severe PHT. There were no differences in baseline demographics between the three pulmonary arterial pressure groups. The presence of moderate-severe PHT predicted increased duration of mechanical ventilation (P = 0.024), worse PaO(2)/F(I)O(2) ratio at 24 h (P = 0.027), and a trend toward increased ICU length of stay (P = 0.055). RVSP was the strongest risk factor for duration of mechanical ventilation and ICU length of stay. There was no difference in 1-year survival amongst the three pulmonary arterial pressure groups.
CONCLUSIONS: Preoperative moderate-severe PHT predicts prolonged duration of mechanical ventilation following lung transplantation in COPD subjects.

Entities:  

Mesh:

Year:  2012        PMID: 23064489     DOI: 10.1007/s00408-012-9423-7

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  47 in total

1.  Cardiopulmonary bypass for bilateral sequential lung transplantation in patients with chronic obstructive pulmonary disease without adverse effect on lung function or clinical outcome.

Authors:  Wilson Y Szeto; Daniel Kreisel; Giorgos C Karakousis; Alberto Pochettino; Daniel H Sterman; Robert M Kotloff; Selim M Arcasoy; David A Zisman; Nancy P Blumenthal; Robert J Gallop; Larry R Kaiser; Joseph E Bavaria; Bruce R Rosengard
Journal:  J Thorac Cardiovasc Surg       Date:  2002-08       Impact factor: 5.209

2.  The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011.

Authors:  Jason D Christie; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2011-10       Impact factor: 10.247

3.  The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010.

Authors:  Jason D Christie; Leah B Edwards; Anna Y Kucheryavaya; Paul Aurora; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2010-10       Impact factor: 10.247

4.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

Authors:  Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2009-01-22       Impact factor: 21.405

5.  Evaluation of the oxygenation ratio in the definition of early graft dysfunction after lung transplantation.

Authors:  Takahiro Oto; Bronwyn J Levvey; David V Pilcher; Michael J Bailey; Gregory I Snell
Journal:  J Thorac Cardiovasc Surg       Date:  2005-07       Impact factor: 5.209

6.  Predicting ICU length of stay following single lung transplantation.

Authors:  K H Lee; G D Martich; A J Boujoukos; R J Keenan; B P Griffith
Journal:  Chest       Date:  1996-10       Impact factor: 9.410

7.  Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis.

Authors:  Adam Fang; Sean Studer; Steven M Kawut; Vivek N Ahya; James Lee; Keith Wille; Vibha Lama; Lorraine Ware; Jonathan Orens; Ann Weinacker; Scott M Palmer; Maria Crespo; David J Lederer; Clifford S Deutschman; Benjamin A Kohl; Scarlett Bellamy; Ejigayehu Demissie; Jason D Christie
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

8.  Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome.

Authors:  Steven M Fiser; Curtis G Tribble; Stewart M Long; Aditya K Kaza; John A Kern; David R Jones; Mark K Robbins; Irving L Kron
Journal:  Ann Thorac Surg       Date:  2002-04       Impact factor: 4.330

9.  Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation.

Authors:  S S Huerd; T N Hodges; F L Grover; J R Mault; M B Mitchell; D N Campbell; S Aziz; P Chetham; F Torres; M R Zamora
Journal:  J Thorac Cardiovasc Surg       Date:  2000-03       Impact factor: 5.209

10.  Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation.

Authors:  Steven M Kawut; Jeffrey Okun; Daichi Shimbo; David J Lederer; Joao De Andrade; Vibha Lama; Ashish Shah; Aaron Milstone; Lorraine B Ware; Ann Weinacker; Ejigayehu Demissie; Jason D Christie
Journal:  Chest       Date:  2009-03-02       Impact factor: 9.410

View more
  1 in total

Review 1.  Epidemiology and clinical impact of major comorbidities in patients with COPD.

Authors:  Miranda Caroline Smith; Jeremy P Wrobel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-08-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.